Tellgen

Tellgen Operating Expenses

The Total Operating Expenses of Tellgen (300642.SZ) as of Oct 31, 2026 is 93.67 M CNY. In the previous year, Total Operating Expenses was 97.24 M CNY — a change of -3.67% (lower).

Operating Expenses

93.67 MCNY

YoY

-3.67%

Last updated:

Total Operating Expenses of Tellgen is 2025 93.67 M CNY. Total Operating Expenses of Tellgen was 2024 97.24 M CNY. It decreases by -3.67% lower compared to the previous year.

The Tellgen Operating Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Expenses
Date
Operating Expenses
Jan 1, 2018
63.50 M CNY
Jan 1, 2019
73.55 M CNY
Jan 1, 2020
85.08 M CNY
Jan 1, 2021
116.57 M CNY
Jan 1, 2022
116.56 M CNY
Jan 1, 2023
109.18 M CNY
Jan 1, 2024
97.24 M CNY
Jan 1, 2025
93.67 M CNY
The Tellgen Operating Expenses history
YEAROperating ExpensesYoY
93.67 MCNY-3.67%
97.24 MCNY-10.94%
109.18 MCNY-6.33%
116.56 MCNY-0.01%
116.57 MCNY+37.02%
85.08 MCNY+15.68%
73.55 MCNY+15.83%
63.50 MCNY+55.86%
40.74 MCNY-26.43%
55.38 MCNY+23.28%
44.92 MCNY-0.61%
45.19 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tellgen Stock analysis

What does Tellgen do? Tellgen Corp develops, manufactures, and markets molecular diagnostic products including immunodiagnostic, molecular diagnostic, and biochemical diagnostic products. Their portfolio features tumor marker detection, HPV nucleic acid testing, autoimmune disease detection, and lung cancer methylation mutation detection products. The company targets healthcare providers and laboratories seeking advanced diagnostic solutions for disease detection and monitoring. Tellgen Corp generates revenue through the sale of these specialized diagnostic products to medical institutions and healthcare facilities. The firm's product lines focus on specific diagnostic needs such as cancer screening and infectious disease testing. Immunodiagnostic products detect antibodies and antigens, molecular diagnostic products analyze genetic material, and biochemical diagnostic products measure metabolic markers. Tellgen Corp sells these products directly to hospitals, clinics, and diagnostic laboratories across China and potentially internationally. Tellgen Corp's revenue streams come from the commercialization of its diagnostic product portfolio. The company's offerings address key healthcare challenges including early cancer detection and infectious disease management. Their products are designed to support clinical decision-making and patient care pathways in medical settings. Tellgen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tellgen stock

Total Operating Expenses of Tellgen is 93.67 M CNY in 2025.

Total Operating Expenses of Tellgen changed from 97.24 M CNY to 93.67 M CNY, representing a -3.67% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Operating Expenses Tellgen since 2006 – with annual values, charts, and detailed analysis.

Operating expenses are the costs incurred in the normal course of business operations, including COGS, SG&A, R&D, and depreciation.

Total Operating Expenses's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Operating Expenses's Tellgen historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Tellgen

All Key Metrics — Tellgen